JP7291145B2 - Ｔｌｒ阻害剤として有効な置換されたインドール化合物 - Google Patents

Ｔｌｒ阻害剤として有効な置換されたインドール化合物 Download PDF

Info

Publication number
JP7291145B2
JP7291145B2 JP2020534224A JP2020534224A JP7291145B2 JP 7291145 B2 JP7291145 B2 JP 7291145B2 JP 2020534224 A JP2020534224 A JP 2020534224A JP 2020534224 A JP2020534224 A JP 2020534224A JP 7291145 B2 JP7291145 B2 JP 7291145B2
Authority
JP
Japan
Prior art keywords
isopropyl
indol
triazolo
pyridin
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020534224A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021506889A5 (https=
JP2021506889A (ja
Inventor
アラリック・ジェイ・ディックマン
ダームパル・エス・ドッド
クリストファー・ピー・マッサリ
ジョン・エル・ギルモア
タシル・シャムスル・ハーク
トレバー・シー・シャーウッド
ブライアン・ケイ・ホワイトリー
ショシャナ・エル・ポージー
スリーカンタ・ラトナ・クマール
ラクスマン・パスヌーリ
スリニバサン・クンチタパタム・ドゥライサミー
スブラマニア・ヘグデ
ルシト・クマール・アヌムラ
ピタニ・ビーラ・ベンカタ・スリニバス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2021506889A publication Critical patent/JP2021506889A/ja
Publication of JP2021506889A5 publication Critical patent/JP2021506889A5/ja
Application granted granted Critical
Publication of JP7291145B2 publication Critical patent/JP7291145B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2020534224A 2017-12-19 2018-12-18 Ｔｌｒ阻害剤として有効な置換されたインドール化合物 Active JP7291145B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607472P 2017-12-19 2017-12-19
US62/607,472 2017-12-19
PCT/US2018/066149 WO2019126113A1 (en) 2017-12-19 2018-12-18 Substituted indole compounds useful as tlr inhibitors

Publications (3)

Publication Number Publication Date
JP2021506889A JP2021506889A (ja) 2021-02-22
JP2021506889A5 JP2021506889A5 (https=) 2021-12-23
JP7291145B2 true JP7291145B2 (ja) 2023-06-14

Family

ID=65003586

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020534224A Active JP7291145B2 (ja) 2017-12-19 2018-12-18 Ｔｌｒ阻害剤として有効な置換されたインドール化合物

Country Status (14)

Country Link
US (1) US11878975B2 (https=)
EP (1) EP3728225B1 (https=)
JP (1) JP7291145B2 (https=)
KR (1) KR102742178B1 (https=)
CN (1) CN111491930B (https=)
AU (1) AU2018390820A1 (https=)
BR (1) BR112020012084A2 (https=)
CA (1) CA3085590A1 (https=)
EA (1) EA202091474A1 (https=)
ES (1) ES2932361T3 (https=)
IL (1) IL275356A (https=)
MX (1) MX2020005462A (https=)
SG (1) SG11202005696YA (https=)
WO (1) WO2019126113A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532145A (ja) * 2019-05-09 2022-07-13 ブリストル－マイヤーズ スクイブ カンパニー 置換ベンズイミダゾロン化合物

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071079B2 (en) 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
JP7304352B2 (ja) * 2017-12-19 2023-07-06 ブリストル－マイヤーズ スクイブ カンパニー ６－アザインドール化合物
EP3728218B1 (en) * 2017-12-20 2021-12-01 Bristol-Myers Squibb Company Amino indole compounds useful as tlr inhibitors
KR102730859B1 (ko) * 2017-12-20 2024-11-15 브리스톨-마이어스 스큅 컴퍼니 아릴 및 헤테로아릴 치환된 인돌 화합물
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
EP3802539B1 (en) 2018-06-05 2023-09-20 F. Hoffmann-La Roche AG Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
EP3807270B1 (en) 2018-06-12 2023-09-13 F. Hoffmann-La Roche AG Novel heteroaryl heterocyclyl compounds for the treatment of autoimmune disease
CN112584903B (zh) 2018-07-23 2025-12-23 豪夫迈·罗氏有限公司 用于自身免疫性疾病治疗的哌嗪化合物
EP3847169A1 (en) 2018-09-04 2021-07-14 F. Hoffmann-La Roche AG Benzothiazole compounds for the treatment of autoimmune diseases
EP3847173B1 (en) 2018-09-06 2023-04-12 F. Hoffmann-La Roche AG Novel pyrazolopyridine compounds for the treatment of autoimmune disease
US11548884B2 (en) 2018-09-06 2023-01-10 Hoffmann-La Roche Inc. Cyclic amidine compounds for the treatment of autoimmune disease
ES2963696T3 (es) * 2018-10-24 2024-04-01 Bristol Myers Squibb Co Compuestos diméricos de indol sustituidos
CN112955450A (zh) 2018-10-24 2021-06-11 百时美施贵宝公司 经取代的吲哚和吲唑化合物
CN114829350B (zh) * 2019-10-04 2024-05-28 百时美施贵宝公司 经取代的咔唑化合物
WO2021084022A1 (en) 2019-10-31 2021-05-06 F. Hoffmann-La Roche Ag Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease
CN114728976B (zh) 2019-11-19 2024-08-16 豪夫迈·罗氏有限公司 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物
WO2021099406A1 (en) 2019-11-20 2021-05-27 F. Hoffmann-La Roche Ag Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease
CN115052860B (zh) * 2020-01-30 2024-06-21 艾尼莫生物科技公司 胶原蛋白1翻译抑制剂和其使用方法
CN116075510A (zh) 2020-08-19 2023-05-05 百时美施贵宝公司 1H-苯并[d]咪唑衍生物作为TLR9抑制剂用于治疗纤维化
AU2021328575A1 (en) 2020-08-19 2023-03-16 Bristol-Myers Squibb Company Imidazo(1,2-a)pyridine and (1,2,4)triazolo(1,5-a)pyridine derivatives as TLR9 inhibitors for the treatment of fibrosis
WO2022040267A1 (en) 2020-08-19 2022-02-24 Bristol-Myers Squibb Company 1h-pyrrolo[3,2-c]pyridine and 1h-pyrrolo[2,3-c]pyridine derivatives as tlr9 inhibitors for the treatment of fibrosis
WO2022140325A1 (en) * 2020-12-22 2022-06-30 Gilead Sciences, Inc. 6-substituted indole compounds
CN116783202A (zh) * 2021-02-09 2023-09-19 吉利德科学公司 噻吩并吡咯化合物
CR20230478A (es) 2021-04-16 2023-11-30 Gilead Sciences Inc Compuestos de tienopirrol.
KR20240056747A (ko) 2021-09-10 2024-04-30 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
MX2024009441A (es) * 2022-02-18 2024-08-14 Bristol Myers Squibb Co Compuestos de imidazopiridinilo sustituidos utiles como inhibidores del receptor tipo toll 9 (tlr9).
CN114591339B (zh) * 2022-05-10 2022-08-02 上海维申医药有限公司 一类Toll样受体抑制剂及其制备和应用
WO2025147320A1 (en) * 2024-01-03 2025-07-10 Kymera Therapeutics, Inc. Stat6 inhibitors and uses thereof

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512369A (ja) 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
JP2005524621A (ja) 2002-01-07 2005-08-18 エーザイ株式会社 デアザプリンおよびそれらの用途
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
JP2006526654A (ja) 2003-06-05 2006-11-24 メルク　エンド　カムパニー　インコーポレーテッド 置換インドールおよび置換インドールの調製方法
JP2008534439A (ja) 2005-01-28 2008-08-28 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
WO2009042092A1 (en) 2007-09-25 2009-04-02 Merck & Co., Inc. 2-aryl or heteroaryl indole derivatives
JP2009526766A (ja) 2006-02-03 2009-07-23 メルク シャープ エンド ドーム リミテッド アルツハイマー病の治療のためのインダゾール誘導体
JP2012504133A (ja) 2008-09-26 2012-02-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾオキサゾール化合物および使用方法
JP2015523981A (ja) 2012-05-31 2015-08-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロピラゾロピリミジン化合物
WO2016151085A1 (en) 2015-03-24 2016-09-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New toll-like receptor 9 antagonists
JP2020529436A (ja) 2017-08-04 2020-10-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ［１，２，４］トリアゾロ［４，３−ａ］ピリジニル置換のインドール化合物
JP2021503004A (ja) 2017-11-14 2021-02-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換インドール化合物
JP6995109B2 (ja) 2016-07-30 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー ジメトキシフェニル置換インドール化合物
JP6995067B2 (ja) 2016-06-29 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［１，５－ａ］ピリジニル置換インドール化合物
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
JP7104775B2 (ja) 2017-08-04 2022-07-21 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
WO2000035886A2 (en) 1998-12-18 2000-06-22 Axys Pharmaceuticals, Inc. (hetero)aryl-bicyclic heteroaryl derivatives, their preparation and their use as protease inhibitors
AU2003239508A1 (en) * 2002-05-21 2003-12-12 Bristol-Myers Squibb Company Indole compounds useful as impdh inhibitors
BRPI0411514A (pt) 2003-06-20 2006-08-01 Coley Pharm Gmbh antagonistas de receptor toll-like de molécula pequena
ZA200701235B (en) * 2004-07-14 2009-10-28 Ptc Therapeutics Inc Methods for treating hepatitis C
CA2648652A1 (en) 2006-04-04 2007-10-11 Myriad Genetics, Inc. Compounds for diseases and disorders
DE102006033109A1 (de) 2006-07-18 2008-01-31 Grünenthal GmbH Substituierte Heteroaryl-Derivate
US8027888B2 (en) 2006-08-31 2011-09-27 Experian Interactive Innovation Center, Llc Online credit card prescreen systems and methods
JP2010511018A (ja) 2006-12-01 2010-04-08 ガラパゴス・ナムローゼ・フェンノートシャップ 変性疾患及び炎症性疾患の治療に有用なトリアゾロピリジン化合物
WO2008152471A1 (en) 2007-06-12 2008-12-18 Coley Pharmaceutical Group, Inc. Quinazoline derivative useful as toll-like receptor antagonist
WO2009030996A1 (en) 2007-09-05 2009-03-12 Coley Pharmaceutical Group, Inc. Triazole compounds as toll-like receptor (tlr) agonists
US8785489B2 (en) 2008-10-17 2014-07-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as MMP-13 inhibitors
TWI462920B (zh) 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JP5864417B2 (ja) 2009-07-16 2016-02-17 マリンクロッド エルエルシー トール様受容体９のアンタゴニストとしての（＋）−モルフィナンおよびその治療的使用
RU2012116207A (ru) 2009-09-24 2013-10-27 Ф.Хоффманн-Ля Рош Аг Производные индола в качестве модуляторов crac
MX2012004792A (es) 2009-10-22 2013-02-01 Vertex Pharma Composiciones para el tratamiento de fibrosis quistica y otras enfermedades cronicas.
WO2012054862A2 (en) 2010-10-21 2012-04-26 The Brigham And Women's Hospital, Inc. Agents, compositions, and methods for treating pruritis and related skin conditions
DK2663550T3 (en) 2011-01-12 2017-03-27 Ventirx Pharmaceuticals Inc SUBSTITUTED BENZOAZEPINS AS MODULATORS OF TOLL-LIKE RECEPTORS
CN103562201B (zh) 2011-01-12 2016-10-19 帆德制药股份有限公司 作为toll样受体调节剂的取代的苯并氮杂卓
WO2012167053A1 (en) 2011-06-01 2012-12-06 Janus Biotherapeutics, Inc. Novel immune system modulators
KR102052215B1 (ko) 2011-06-01 2019-12-04 야누스 바이오테라퓨틱스, 인크. 신규한 면역 시스템 조절제
KR101913619B1 (ko) 2011-06-09 2018-12-28 리젠 파마슈티컬스 소시에떼 아노님 Gpr-119의 조절제로서의 신규한 화합물
KR101913135B1 (ko) 2011-07-15 2018-10-30 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조절 인자로서의 신규의 치환 인돌 유도체
WO2013052550A2 (en) 2011-10-04 2013-04-11 Janus Biotherapeutics, Inc. Novel imidazole quinoline-based immune system modulators
TWI619704B (zh) 2012-05-18 2018-04-01 大日本住友製藥股份有限公司 羧酸化合物
EP2738172A1 (en) 2012-11-28 2014-06-04 Almirall, S.A. New bicyclic compounds as crac channel modulators
JP6223563B2 (ja) 2013-10-14 2017-11-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 選択的に置換されたキノリン化合物
CN105992766A (zh) 2013-12-13 2016-10-05 武田药品工业株式会社 作为tlr抑制剂的吡咯并[3,2-c]吡啶衍生物
HUE054672T2 (hu) 2014-08-15 2021-09-28 Chia Tai Tianqing Pharmaceutical Group Co Ltd TLR7 agonistaként alkalmazott pirrolopirimidin vegyületek
EP3398948A3 (en) 2014-08-22 2018-12-05 Janus Biotherapeutics, Inc. 2,4,6,7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof

Patent Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003512369A (ja) 1999-10-19 2003-04-02 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
JP2005524621A (ja) 2002-01-07 2005-08-18 エーザイ株式会社 デアザプリンおよびそれらの用途
JP2006526654A (ja) 2003-06-05 2006-11-24 メルク　エンド　カムパニー　インコーポレーテッド 置換インドールおよび置換インドールの調製方法
JP2008534439A (ja) 2005-01-28 2008-08-28 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
WO2006113458A1 (en) 2005-04-15 2006-10-26 Bristol-Myers Squibb Company Heterocyclic inhibitors of protein arginine methyl transferases
JP2009526766A (ja) 2006-02-03 2009-07-23 メルク シャープ エンド ドーム リミテッド アルツハイマー病の治療のためのインダゾール誘導体
WO2009042092A1 (en) 2007-09-25 2009-04-02 Merck & Co., Inc. 2-aryl or heteroaryl indole derivatives
JP2012504133A (ja) 2008-09-26 2012-02-16 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾオキサゾール化合物および使用方法
JP2015523981A (ja) 2012-05-31 2015-08-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 テトラヒドロピラゾロピリミジン化合物
WO2016151085A1 (en) 2015-03-24 2016-09-29 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. New toll-like receptor 9 antagonists
JP6995067B2 (ja) 2016-06-29 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー ［１，２，４］トリアゾロ［１，５－ａ］ピリジニル置換インドール化合物
JP6995109B2 (ja) 2016-07-30 2022-01-14 ブリストル－マイヤーズ スクイブ カンパニー ジメトキシフェニル置換インドール化合物
JP7028861B2 (ja) 2016-09-09 2022-03-02 ブリストル－マイヤーズ スクイブ カンパニー ピリジル置換のインドール化合物
JP2020529436A (ja) 2017-08-04 2020-10-08 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ［１，２，４］トリアゾロ［４，３−ａ］ピリジニル置換のインドール化合物
JP7104775B2 (ja) 2017-08-04 2022-07-21 ブリストル－マイヤーズ スクイブ カンパニー Ｔｌｒ７／８／９の阻害剤として有用な置換インドール化合物
JP2021503004A (ja) 2017-11-14 2021-02-04 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換インドール化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Bioorganic & Medicinal Chemistry Letters，2006年，Vol.16, No.22，pp.5907-5912

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022532145A (ja) * 2019-05-09 2022-07-13 ブリストル－マイヤーズ スクイブ カンパニー 置換ベンズイミダゾロン化合物
JP7621275B2 (ja) 2019-05-09 2025-01-24 ブリストル－マイヤーズ スクイブ カンパニー 置換ベンズイミダゾロン化合物

Also Published As

Publication number Publication date
EP3728225B1 (en) 2022-11-09
EP3728225A1 (en) 2020-10-28
KR20200101402A (ko) 2020-08-27
IL275356A (en) 2020-07-30
WO2019126113A1 (en) 2019-06-27
AU2018390820A1 (en) 2020-08-06
CN111491930B (zh) 2023-09-26
EA202091474A1 (ru) 2020-11-18
JP2021506889A (ja) 2021-02-22
CA3085590A1 (en) 2019-06-27
US20200308172A1 (en) 2020-10-01
MX2020005462A (es) 2020-09-07
ES2932361T3 (es) 2023-01-18
KR102742178B1 (ko) 2024-12-12
US11878975B2 (en) 2024-01-23
BR112020012084A2 (pt) 2020-11-24
CN111491930A (zh) 2020-08-04
SG11202005696YA (en) 2020-07-29

Similar Documents

Publication Publication Date Title
JP7291145B2 (ja) Ｔｌｒ阻害剤として有効な置換されたインドール化合物
US11820768B2 (en) 4-azaindole compounds
JP7313354B2 (ja) Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物
JP7287964B2 (ja) 置換インドールエーテル化合物
JP7304352B2 (ja) ６－アザインドール化合物
JP2019523241A (ja) ［１，２，４］トリアゾロ［１，５−ａ］ピリジニル置換インドール化合物
WO2019028301A1 (en) INDOLE COMPOUNDS SUBSTITUTED WITH [1,2,4] TRIAZOLO [4,3-A] PYRIDINYL
EP4051388A1 (en) Substituted pyrazole compounds as toll receptor inhibitors
KR102904576B1 (ko) 치환된 벤즈이미다졸론 화합물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211110

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221020

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230221

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230602

R150 Certificate of patent or registration of utility model

Ref document number: 7291145

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150